Highlights
Growth factor signaling causes sustained nuclear ERK1/2 activation.
The SCR and BCR/ABL inhibitor dasatinib blocks ERK1/2 and represses cell invasion.
EGF-stimulated cells may escape dasatinib inhibition of invasion through mesenchymal to amoeboid transition.
Combined inhibition of SRC and Rho-kinase signaling is necessary to completely block EGF-induced invasion.